Last updated on December 2019

A Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Brief description of study

The primary objective of this study is to evaluate the safety, tolerability of single-ascending doses of BIIB100 in adults with amyotrophic lateral sclerosis (ALS). The secondary objective of the study is to characterize the pharmacokinetic profile of BIIB100.

Clinical Study Identifier: NCT03945279

Find a site near you

Start Over

Research Site

Boston, MA United States
  Connect »